Clinical trials: Nash
Metabolic Associated Fatty Liver Disease
Lifestyle Modification for MAFLD Based on TTM
Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment.Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight…
- Trial name
- NCT04871880
- Testing
- Dietitian led life style modification intervention, Conventional care (control)
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Fatty Liver Disease
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity.
- Trial name
- MASLD (NCT06720766)
- Testing
- FibbroScan and biopsy
- Where
- China
- Volunteers
- 565 people
- Sponsor
- The Third People's Hospital of Chengdu
NAFLD
Polyunsaturated Fatty Acids in Patients With NAFLD.
Patients with metabolic syndrome and Nonalcoholic fatty liver disease (NAFLD) will be randomly allocated for the treatment with n-3 PUFA (3.6 g/day) or placebo for 12 months.
- Trial name
- NCT02647294
- Testing
- Maxicor
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- General University Hospital, Prague
Arterial Hypertension, Atherosclerosis Occlusive Disease
Gut Microbiota in Chronic Noncommunicable Diseases
It is an observational study in patients with chronic noncommunicable diseases (i.e. cardiovascular diseases, diabetes mellitus, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease and asthma ) and control…
- Conditions
- Arterial Hypertension, Atherosclerosis Occlusive Disease, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
- Trial name
- NCT04820556
- Where
- 2 sites in Russia
- Volunteers
- 1,084 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Lysosomal Acid Lipase Deficiency
A Study to Identify and Characterize LAL-D Patients in High-risk Populations
The objective of this study is to determine the frequency of Lysosomal Acid Lipase Deficiency (LAL D) by lysosomal acid lipase (LAL) enzyme activity assay in patients who are considered to be at risk.
- Trial name
- NCT02345421
- Where
- 15 sites in United States
- Volunteers
- 640 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Metabolic Dysfunction Associated Fatty Liver Disease, Compensated Liver Cirrhosis
The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
A total of 195 adult patients with biopsy-proven or clinically diagnosed metabolic dysfunction-associated with fatty liver disease(MAFLD)-related cirrhosis will be randomly divided into two arms.
- Trial name
- NCT06773221
- Testing
- Chiglitazar 64mg
- Where
- 4 sites in China
- Volunteers
- 195 people
- Sponsor
- Beijing Friendship Hospital
Effect of Vitamin A and Calcium in Patients With Non-alcoholic Fatty Liver Patients
Effect of Vitamin A and Calcium in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease at a global scale and is strongly associated with the obesity and metabolic syndrome .
- Trial name
- NCT06031532
- Where
- Egypt
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Sohag University
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT04501406
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- University of Florida
NAFLD, Non-alcoholic Fatty Liver Disease
Manual Therapy in Metabolic Liver Disease
Hepatic steatosis is a disease that is becoming more common in our society; approximately 40% of the population suffers from non-alcoholic fatty liver.
- Trial name
- OSTEO-EHMet (NCT06338618)
- Testing
- liver treatment protocol
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- University of Seville
Fatty Liver Disease, Fatty Liver
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD
- Trial name
- MAFLD (NCT05966025)
- Testing
- Itopride, conventional therapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- October 6 University
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
The aim is to determine the metabolic factors, host immune factors, and medical imaging data associated with the development of HepatoCellular Carcinoma (HCC) in patients with alcohol-related liver disease or dysmetabolic…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Alcohol-related Liver Disease, Cirrhosis, Liver
- Trial name
- CHALNA2 (NCT05623150)
- Testing
- Liver biopsy
- Where
- France
- Volunteers
- 710 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Nonalcoholic Fatty Liver Disease, Liver Steatosis
Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis
Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China.
- Conditions
- Nonalcoholic Fatty Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT03386890
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b
Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）
This is a prospective, multicenter, open-label, non-randomized controlled real-world study to explore the efficacy and safety and to accumulate more evidence-based medical data of an antiviral treatment programme for chronic…
- Trial name
- NCT06368882
- Testing
- Peg-Interferon α
- Where
- 5 sites in China
- Volunteers
- 1,500 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Liver Steatoses, Liver Metastasis Colon Cancer
Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis
Non-alcoholic fatty liver disease is becoming increasingly common in Canada and throughout the world. Fatty liver can increase the risks of perioperative complications for those who need liver surgery.
- Conditions
- Liver Steatoses, Liver Metastasis Colon Cancer, NAFLD
- Trial name
- NCT05884723
- Testing
- Ketogenic Diet
- Where
- Canada
- Volunteers
- 124 people
- Sponsor
- Anton Skaro
Fatty Liver
Body Composition and Fatty Liver Disease
This study investigates relationship between fatty liver prognosis and body composition analysis result based on non-contrast low dose CT in patients with fatty liver disease.
- Trial name
- NCT05695118
- Testing
- Non-contrast low-dose abdomen CT, Fibroscan, bioelectrical impedance analysis (BIA)
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Seoul National University Hospital
Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)
Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET
This observational study aims to quantify whole-body amino acid and glucose metabolism in healthy adults and in patients with non-alcoholic fatty liver disease (NAFLD) using total-body PET/CT.
- Trial name
- NCT07366710
- Testing
- 18F-FDG (oral), 18F-FDG (intravenous), 18F-FET (oral)
- Where
- Denmark
- Volunteers
- 36 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Non Alcoholic Steatohepatitis
The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
To study the effects of Hesperidin supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI)…
- Trial name
- NCT03377140
- Testing
- Hesperidin, control
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Non-Alcoholic Fatty Liver Disease, Hyperuricemia
Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
Metabolic associated fatty liver disease (MAFLD) is the most common and harmful chronic liver disease, and it is increasingly diagnosed in many developed and developing countries.
- Trial name
- NCT05474560
- Testing
- Allopurinol (100 mg/day) plus lifestyle intervention, Febuxostat 40 mg plus lifestyle intervention, Life style intervention
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Non-Alcoholic Fatty Liver Disease, Insulin Resistance
Effects of Carnitine Supplementation on Liver and Muscle
It will be evaluated whether carnitine, a dietary supplement, reduces liver fat and improves metabolism in individuals who have a high concentration of fat within their liver.
- Trial name
- ECLIPSE (NCT03439917)
- Testing
- L-Carnitine tartrate, Meal Replacement Drink, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Nottingham
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be…
- Trial name
- FLiPP (NCT02754037)
- Testing
- Fluorodeoxyglucose (FDG) positron emission tomography (PET), Magnetic resonance imaging (MRI), PET Explorer
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, Davis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.